Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.
Saumeth CardonaKaterina TsegkaFrancisco J PasquelMaya FayfmanLimin PengSol JacobsPriyathama VellankiMichael HalkosRobert A GuytonVinod H ThouraniRodolfo J GalindoGuillermo E UmpierrezPublished in: BMJ open diabetes research & care (2019)
The use of sitagliptin during the perioperative period did not prevent the development of stress hyperglycemia or need for insulin therapy in patients without diabetes undergoing CABG surgery.
Keyphrases
- ejection fraction
- coronary artery bypass
- type diabetes
- percutaneous coronary intervention
- glycemic control
- cardiovascular disease
- minimally invasive
- acute coronary syndrome
- coronary artery bypass grafting
- cardiac surgery
- coronary artery disease
- chronic kidney disease
- stress induced
- oxidative stress
- adipose tissue
- end stage renal disease
- skeletal muscle
- acute kidney injury
- newly diagnosed
- weight loss
- prognostic factors